Developing DMPK/Tox Sales Channels Through a North American Consortium
First written in FY2016. 14 of 28 entries say "Restated". Latest entry: 2026-08-14.
No other company in this theme has enough history to compare yet.
- FY2024-Q2RestatedAnnual report
「We will continue to develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」
The company has reaffirmed its policy of developing new customers and expanding applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs. - FY2023RestatedAnnual report
「As of the fiscal year ended March 2023, 10 organizations were participating in the consortium established in the United States as a forum for joint research with pharmaceutical companies on the usefulness of PXB mice. We will present the research findings successively at academic conferences and in academic journals and use them to expand distribution channels through promotional activities. While seeking to expand applications through these research findings, we will also promote service expansion by actively pursuing business alliances with CROs that have extensive experience, in order to respond to the various needs of pharmaceutical companies and other customers.」
The company has reaffirmed its policy of expanding distribution channels and applications through the 10-member consortium, presentation of research findings and business alliances with CROs. - FY2023-Q3RestatedAnnual report
「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」
The company has reaffirmed its policy of developing new customers and expanding applications through consortium activities and business alliances with CROs. No progress in the number of participating organizations or business alliances is indicated. - FY2023-Q2RestatedAnnual report
「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」
The company has reaffirmed its policy of expanding overseas distribution channels by developing new customers and expanding applications through consortium activities and business alliances with CROs. - FY2023-Q1RestatedAnnual report
「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」
The company has reaffirmed its policy of expanding overseas distribution channels by developing new customers and expanding applications through consortium activities and business alliances with CROs. - FY2022Disclosed 10 participating organizations in the consortiumAnnual report
「As of the fiscal year ended March 2022, 10 organizations were participating in the consortium established in the United States as a forum for joint research with pharmaceutical companies on the usefulness of PXB mice. We will present the research findings successively at academic conferences and in academic journals and use them to expand distribution channels through promotional activities.」
The company continues its consortium activities, presentation of research findings and policy of expanding distribution channels. It disclosed 10 participating organizations this time. - FY2022-Q1RestatedAnnual report
「To increase sales further, we will develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs.」
The company has reaffirmed its policy of developing new customers and expanding applications through consortium activities and business alliances with CROs. - FY2021AdvancedAnnual report
「As of the fiscal year ended March 2021, 11 organizations were participating in the consortium established in the United States as a forum for joint research with pharmaceutical companies on the usefulness of PXB mice. We will present the research findings successively at academic conferences and in academic journals and use them to expand distribution channels through promotional activities. In addition, we have business alliances with 8 organizations in Japan and overseas to leverage the expertise of CROs with extensive experience.」
The consortium has 11 participating organizations and the company has business alliances with 8 CROs, giving concrete shape to distribution-channel and application development through research presentations and use of its partners' expertise. - FY2021-Q2RestatedAnnual report
「Although overseas net sales have been increasing for the past 3 years, we will further develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs in order to increase sales further.」
The company has reaffirmed its policy of developing new customers and expanding applications through consortium activities and business alliances with CROs. No new milestone is indicated. - FY2021-Q1RaisedAnnual report
「Although overseas net sales have been increasing for the past 3 years, we will further develop new customers and expand applications for PXB mice and PXB-cells through consortium activities and business alliances with CROs in order to increase sales further.」
The company explicitly identifies new-customer development and expansion of applications for PXB mice and PXB-cells through business alliances with CROs, in addition to its existing consortium activities, as means of expanding distribution channels. - FY2020AdvancedAnnual report
「We will present the findings successively at academic conferences and in academic journals and use them to expand our distribution channels through promotional activities in this field.」
The company continues initiatives to use the North American consortium, joint research with overseas pharmaceutical companies, and presentations at academic conferences and in academic journals to expand distribution channels, with a substantial increase in overseas net sales and growth in orders in the safety-testing and related fields indicated. - FY2020-Q3AdvancedAnnual report
「In safety-related fields, which the Group positions as growth areas because they can target many new drugs, orders related to nucleic acid drugs in overseas markets, where the Group is pursuing market development, grew substantially, and orders and revenue exceeded the prior-year period.」
The company states that, while developing overseas markets, orders related to nucleic acid pharmaceuticals grew substantially and orders and net sales exceeded the levels recorded in the same period of the previous year. - FY2020-Q2AdvancedAnnual report
「Orders related to nucleic acid pharmaceuticals grew in overseas markets, and orders and net sales exceeded the levels recorded in the same period of the previous year.」
The company reports progress in the overseas safety-testing and related fields, where orders related to nucleic acid pharmaceuticals increased and orders and net sales exceeded the levels recorded in the same period of the previous year. - FY2020-Q1AdvancedAnnual report
「Under these circumstances, our group provides contract testing services using human hepatocyte chimeric mice in which more than 70% of the mouse liver has been replaced with human hepatocytes, marketed under our product name PXB mice. We have focused on expanding overseas markets, particularly the United States, where major pharmaceutical companies from around the world have research and development facilities.」
The company continues to focus on expanding overseas markets, particularly the United States, and states that orders in the overseas safety-testing and related fields exceeded the plan. - FY2019RestatedAnnual report
「We established a consortium in North America as a forum where pharmaceutical companies with numerous drug candidates can jointly study the usefulness of PXB mice and share their findings, and we continue to conduct research with overseas pharmaceutical companies on the usefulness of PXB mice in DMPK/Tox and biopharmaceutical development. We will present the findings successively at academic conferences and in academic journals and use them to expand our distribution channels through promotional activities in this field.」
The company continues its policy of expanding distribution channels through the North American consortium, joint research with overseas pharmaceutical companies, and presentations at academic conferences and in academic journals. - FY2019-Q3AdvancedAnnual report
「In the Group's current core business, hepatitis testing for pharmacological efficacy evaluation, inquiries have increased, particularly in overseas markets, as pharmaceutical companies have advanced the development of anti-hepatitis B drugs, and both revenue and order intake remained firm above the same period of the previous year.」
The company states that inquiries from overseas markets increased and that net sales and orders exceeded the levels recorded in the same period of the previous year, indicating progress in developing overseas distribution channels. - FY2019-Q1AdvancedAnnual report
「Our group provides contract testing services using human hepatocyte chimeric mice in which more than 70% of the mouse liver has been replaced with human hepatocytes, marketed under our product name PXB mice. We have focused on expanding overseas markets, particularly the United States, where major pharmaceutical companies from around the world have research and development facilities. Overseas order backlog was substantially higher than in the same period of the previous year, reflecting several large orders.」
The company states that it continues to focus on expanding overseas markets, particularly the United States, and that overseas order backlog was substantially higher than in the same period of the previous year due to several large orders. The filing indicates concrete progress in developing overseas distribution channels. - FY2018RestatedAnnual report
「Going forward, we will present the research findings at academic conferences and publish them in academic journals, and will work to expand our distribution channels through promotional activities in this field.」
The company continues initiatives to present the results of joint research through the North American consortium at academic conferences and in publications, using them for promotion and distribution-channel expansion. - FY2018-Q3RestatedAnnual report
「DMPK/Tox testing, which our group positions as a growth area because it covers many drug candidates, comprises pharmacokinetics-related and safety testing. We established a consortium, CMHL Consortium LLC, as a forum for validating the usefulness of PXB mice and conduct joint research with pharmaceutical companies and others. Research on PXB mice presented at academic conferences and published in journals serves as promotion to researchers at pharmaceutical companies and others, helping to raise awareness of PXB mice in the DMPK/Tox field, which covers a broad range of testing areas.」
The company continues joint research through CMHL Consortium LLC and efforts to raise awareness in the DMPK/Tox field through conference presentations and academic publications. - FY2018-Q2RestatedAnnual report
「DMPK/Tox testing, which our group positions as a growth area because it covers many drug candidates, comprises pharmacokinetics-related and safety testing. We established a consortium, CMHL Consortium LLC, as a forum for validating the usefulness of PXB mice and conduct joint research with pharmaceutical companies and others. Research on PXB mice presented at academic conferences and published in journals serves as promotion to researchers at pharmaceutical companies and others, helping to raise awareness of PXB mice in the DMPK/Tox field, which covers a broad range of testing areas.」
The company continues joint research through CMHL Consortium LLC and efforts to raise awareness in the DMPK/Tox field through conference presentations and academic publications. - FY2018-Q1AdvancedAnnual report
「Our group provides contract testing services using human hepatocyte chimeric mice in which more than 70% of the mouse liver has been replaced with human hepatocytes, marketed under our product name PXB mice. We established a consortium, CMHL Consortium LLC, as a forum for validating the usefulness of PXB mice and conduct joint research with pharmaceutical companies and others. Research on PXB mice presented at academic conferences and published in journals serves as promotion to researchers at pharmaceutical companies and others, helping to raise awareness of PXB mice in the DMPK/Tox field, which covers a broad range of testing areas. Research findings presented at a domestic academic conference in the previous fiscal year led to an order.」
The company states that it continues to use joint research with pharmaceutical companies and others through the consortium, as well as conference presentations and academic publications, to develop distribution channels, and that research findings presented at a domestic conference led to an actual order. - FY2017RestatedAnnual report
「Going forward, we will present the research findings at academic conferences and publish them in academic journals, and will work to expand our distribution channels through promotional activities in this field.」
The company has reaffirmed its policy of expanding distribution channels through conference presentations, academic publications and promotional activities based on joint research conducted through the North American consortium. - FY2017-Q3RestatedAnnual report
「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」
The company reiterates the launch of sales and consortium activities as means of developing distribution channels in the DMPK/Tox field. - FY2017-Q2RestatedAnnual report
「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」
The company reiterates the launch of consortium activities and sales activities targeting pharmaceutical companies, but this filing does not indicate any new milestone. - FY2017-Q1AdvancedAnnual report
「DMPK/Tox testing (drug metabolism and pharmacokinetics-related testing and safety testing) is positioned as a future growth area because it can target more new drugs than hepatitis testing. The Company is conducting sales activities with pharmaceutical companies and has begun consortium activities to jointly research the usefulness of PXB mice.」
The company explicitly states that, in addition to sales activities targeting pharmaceutical companies, it has launched a consortium to jointly study the usefulness of PXB mice. - FY2016AdvancedAnnual report
「We have established a consortium in North America as a forum where pharmaceutical companies with numerous drug candidates can jointly study the usefulness of PXB mice and share their findings. We will conduct promotional activities in this field and work to expand our distribution channels.」
The North American consortium has been established, and the company is sharing joint research findings and expanding distribution channels through promotional activities.